Biogen Inc. $BIIB Stock: Yousif Capital Management LLC Grows Position

Yousif Capital Management LLC increased its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 1,813.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 270,457 shares of the biotechnology company’s stock after purchasing an additional 256,323 shares during the period. Biogen accounts for 0.7% of Yousif Capital Management LLC’s investment portfolio, making the stock its 22nd largest holding. Yousif Capital Management LLC’s holdings in Biogen were worth $61,091,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. BlackRock Inc. purchased a new position in Biogen during the 2nd quarter worth $3,453,878,000. Primecap Management Co. CA purchased a new stake in shares of Biogen in the second quarter valued at about $3,274,304,000. Wellington Management Group LLP raised its holdings in shares of Biogen by 5.3% in the second quarter. Wellington Management Group LLP now owns 3,117,469 shares of the biotechnology company’s stock valued at $673,560,000 after buying an additional 155,828 shares during the last quarter. Amundi boosted its stake in shares of Biogen by 91.8% during the second quarter. Amundi now owns 1,516,831 shares of the biotechnology company’s stock worth $327,727,000 after buying an additional 726,004 shares during the period. Finally, Legal & General Group Plc acquired a new stake in shares of Biogen during the second quarter worth about $322,640,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Stock Performance

Shares of Biogen stock traded down $3.15 on Friday, reaching $250.69. 1,157,351 shares of the stock were exchanged, compared to its average volume of 1,296,961. Biogen Inc. has a 1-year low of $138.00 and a 1-year high of $254.41. The company has a current ratio of 1.87, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39. The business has a fifty day moving average price of $223.60 and a two-hundred day moving average price of $206.04. The firm has a market capitalization of $37.04 billion, a PE ratio of 44.37, a PEG ratio of 2.83 and a beta of 0.09.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, beating analysts’ consensus estimates of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The firm had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. During the same quarter last year, the firm earned $5.47 earnings per share. The firm’s revenue was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, research analysts anticipate that Biogen Inc. will post 12.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BIIB has been the topic of a number of research reports. Wedbush raised their price target on Biogen from $201.00 to $215.00 and gave the stock a “neutral” rating in a report on Thursday, July 30th. Barclays upped their price objective on Biogen from $185.00 to $200.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 29th. Zacks Research raised Biogen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 28th. Bank of America lifted their target price on Biogen from $219.00 to $244.00 and gave the company a “neutral” rating in a research note on Thursday. Finally, JPMorgan Chase & Co. raised Biogen from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $210.00 to $300.00 in a report on Monday, October 12th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $241.89.

About Biogen

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.